A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00959699
First received: July 29, 2009
Last updated: January 23, 2014
Last verified: January 2014

July 29, 2009
January 23, 2014
November 2009
May 2012   (final data collection date for primary outcome measure)
Percentage of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24 (FW24) Among Randomized Participants Who Received At Least One Dose of Trial Medication [ Time Frame: Up to Week 72 ] [ Designated as safety issue: No ]
SVR24 is defined as undetectable plasma hepatitis C virus ribonucleic acid (HCV-RNA) at 24 weeks after the end of all study treatment. If there was no value in the FW24 visit window, the closest value available chronologically after this window was used; if a value was still missing after that, the value from Follow-up Week 12 (FW12) was used. HCV-RNA is detected by a nucleic acid amplification test and the lower limit of detection for this assay is 9.3 IU/mL.
To compare 24 week follow-up HCV-RNA level after treatment w/ boceprevir in combo w/ PEG2b plus ribavirin weight-based dosing to treatment with PEG2b plus ribavirin alone in adult subjects coinfected w/ HIV & previously untreated chronic HCV genotype 1 [ Time Frame: 24 weeks after treatment ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00959699 on ClinicalTrials.gov Archive Site
  • Percentage of Participants Achieving SVR24 Among Randomized Participants Who Received At Least One Dose of Boceprevir (Experimental) or Placebo (Control) [ Time Frame: Up to Week 72 ] [ Designated as safety issue: No ]
    SVR24 is defined as undetectable plasma HCV-RNA 24 weeks after the end of all study treatment. If there was no value in the FW24 visit window, the closest value available chronologically after this window was used; if a value was still missing after that, the value from FW12 was used. HCV-RNA is detected by a nucleic acid amplification test and the lower limit of detection for this assay is 9.3 IU/mL.
  • Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR24 [ Time Frame: Up to Week 12 ] [ Designated as safety issue: No ]
    EVR was defined as undetectable HCV-RNA at Treatment Week (TW) 2, 4, 8, or 12. HCV-RNA was detected by a nucleic acid amplification test and the lower limit of detection for this assay is 9.3 IU/mL.
  • Percentage of Participants With Undetectable HCV-RNA at Follow-up Week 12 (FW12) [ Time Frame: Up to Week 60 ] [ Designated as safety issue: No ]
    The virologic response at FW12 was considered SVR12 with an additional rule for handling missing data: participants with missing HCV-RNA assessment at FW12 but having non-missing, undetectable HCV-RNA assessments at both FW4 and FW24, were assumed to be responders for SVR12. HCV-RNA was detected by a nucleic acid amplification test and the lower limit of detection for this assay is 9.3 IU/mL.
  • Change From Baseline in log10 HCV-RNA at Treatment Week 4 (TW4) [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    This is a measure of the change in the amount of HCV-RNA in the plasma at the end of 4 weeks of treatment. HCV-RNA was detected by a nucleic acid amplification test and the lower limit of detection for this assay is 9.3 IU/mL.
  • Percentage of Participants With HCV Virologic Breakthrough or Incomplete Virologic Response/Rebound [ Time Frame: Up to Week 72 ] [ Designated as safety issue: No ]
    Virologic breakthrough is defined as achieving undetectable HCV-RNA and subsequently having an HCV-RNA level of >1000 IU/mL. Incomplete Virologic Response/Rebound is defined as having a one log10 increase in HCV-RNA from the participant's nadir, with an HCV-RNA >1000 IU/mL. HCV-RNA was detected by a nucleic acid amplification test and the lower limit of detection for this assay is 9.3 IU/mL.
Not Provided
Not Provided
Not Provided
 
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (Protocol No. P05411)

The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC) plus weight-based dosing (WBD) of ribavirin (RBV) (600 mg/day to 1400 mg/day) PO to therapy with PegIFN-2b + RBV alone in adult participants coinfected with human immunodeficiency virus (HIV) and previously untreated chronic hepatitis C virus (HCV) genotype 1.

Boceprevir is a potent, orally administered, novel serine protease inhibitor, specifically designed to inhibit the HCV nonstructural protein 3 (NS3) protease and, thereby, inhibit viral replication in HCV-infected host cells. The mechanism of inhibition represents a new mechanism of action compared to both interferon alfa and ribavirin. Based on previous experience with PegIFN-2b and RBV in combination with boceprevir in the HCV-monoinfected population, this combination treatment is expected to provide significant benefit to the HIV/HCV coinfected population. Given the high unmet medical need of these participants and the benefit of the addition of boceprevir to PegIFN-2b/RBV, it is important to demonstrate the safety and efficacy of boceprevir in combination with PegIFN-2b/RBV in participants coinfected with HIV/HCV.

This is a randomized, multi-center trial, double-blinded for boceprevir or placebo in combination with open-label PegIFN-2b/RBV in participants coinfected with HIV and previously untreated chronic HCV (genotype 1), to be conducted in conformance with Good Clinical Practice (GCP). This trial consists of two arms, one control arm (Arm 1) and one experimental arm (Arm 2). Participants in the control arm (Arm 1) may receive boceprevir/PegIFN-2b/RBV via a crossover arm.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • HIV Infections
  • Hepatitis C
  • HCV Infection
  • Drug: PegIFN-2b
    PegIFN-2b (1.5 μg/kg/week subcutaneously)
    Other Names:
    • SCH 054031
    • MK-4031
    • Pegylated interferon alfa-2b
    • Peginterferon alfa-2b
  • Drug: RBV
    Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
    Other Name: Ribavirin
  • Drug: Placebo to Boceprevir
    Placebo to boceprevir (orally, three times per day)
  • Drug: Boceprevir
    Boceprevir (800 mg, orally, three times per day)
    Other Names:
    • SCH 503034
    • MK-3034
    • Victrelis
  • Placebo Comparator: PegIFN-2b + RBV
    PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600-1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by placebo to boceprevir plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up (Control Arm). Participants who do not achieve HCV-RNA <9.3 IU/mL by Treatment Week 24 (TW24) are eligible to cross-over and receive boceprevir along with the PegIFN-2b and RBV for up to 44 weeks.
    Interventions:
    • Drug: PegIFN-2b
    • Drug: RBV
    • Drug: Placebo to Boceprevir
  • Active Comparator: PegIFN-2b + RBV + Boceprevir
    PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600- 1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by boceprevir (800 mg, orally, 3 times per day) plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up.
    Interventions:
    • Drug: PegIFN-2b
    • Drug: RBV
    • Drug: Boceprevir
Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
99
October 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • >=18 and <=65 years of age
  • Body weight >=40 and <=125 kg
  • Documented history of HIV infection for greater than 6 months prior to Day 1
  • On an optimized anti-retroviral treatment regimen (OTR) with stable HIV disease with CD4 >=200 cells/µL and HIV-1 RNA viral load <50 copies/mL
  • Documented chronic hepatitis C (CHC) genotype 1 infection (greater than 6 months prior to Day 1)
  • Use of acceptable methods of contraception 2 weeks prior to Day 1 and at least 6 months or longer after treatment
  • Liver biopsy with histology consistent with CHC and no other etiology

Exclusion Criteria:

  • Participants who received prior treatment for hepatitis C other than herbal remedies except those with known hepatotoxicity
  • Coinfected with hepatitis B virus (Hepatitis B surface antigen (HBsAg) positive) and/or demonstrating signs and symptoms consistent with concomitant infection
  • Evidence of decompensated liver disease
  • Participants who have changed their anti-retroviral regimen within the last 3 months prior to Day 1 or had first initiated anti-retroviral therapy within the last 6 months prior to Day 1
  • Use of certain HIV medications will not be allowed. Medications will be reviewed by the Investigator
  • History of clinically significant opportunistic infections (except oral thrush) within the last year prior to Day 1
  • Current evidence of substance abuse within 3 years of the Screening Visit
  • History of a clinical diagnosis within the past 6 months of substance abuse prior to Day 1
  • Participants receiving opiate agonist substitution therapy but not enrolled in an opiate substitution maintenance program
  • History of marijuana use deemed excessive by the Investigator
  • Infected with HIV-2
  • Use of any HIV protease inhibitor without the coadministration of ritonavir within one month of Day 1 and throughout the period of the trial
  • Participants receiving any of the following medication(s) within 2 weeks prior to the Day 1 visit: alfuzosin, antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, and quinidine), ergot derivatives, cisapride, lovastatin, simvastatin, pimozide, triazolam, and orally administered midazolam.

Key Laboratory Exclusion Criteria:

  • Hematologic, biochemical, and serologic criteria (growth factors may not be used to achieve trial entry requirements):

    • Hemoglobin <11 g/dL for females and <12 g/dL for males
    • Neutrophils <1500/mm^3 (blacks/African-Americans: <1200/mm^3)
    • Platelets <100,000/mm^3
    • Direct bilirubin >1.5 x ULN (upper limit of normal) of the laboratory reference range. Total bilirubin >1.6 mg/dL unless history of Gilbert's disease or antiretroviral regimen contains atazanavir. If Gilbert's disease is the proposed etiology, this must be documented in the participant's chart
  • Alpha fetoprotein (AFP):

    • AFP >100 ng/mL OR
    • AFP 50 to 100 ng/mL (requires a liver ultrasound and participants with findings suspicious for hepatocellular carcinoma are excluded)
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00959699
P05411, MK-3034-025
Yes
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP